Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Zealand Pharma

Tracked across 9 events · 137 articles · First seen Apr 19, 2026 · Last active Sep 21, 2026

Sentiment
10
Attention
6
Events
9
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
6 30
Tech
Impact: Zealand Pharma is presenting Phase 2 ZUPREME-1 data on petrelintide, a key drug candidate in its obesity and metabolic health pipeline, at a significant scientific conference. This presentation could enhance its reputation and potentially its stock value if the data is well-received.
May 27, 2026 · 19 articles
2 0
Business
Impact: Zealand Pharma is the company disclosing transactions in its shares by persons discharging managerial responsibilities and/or their closely associated persons.
May 29, 2026 · 6 articles
0 0
Regulatory
Impact: Zealand Pharma is the subject of the announcement, disclosing its treasury share holdings. The event is a routine regulatory disclosure with no material impact on the company.
Aug 24, 2026 · 6 articles
4 55
Regulatory
Zealand Pharma announced on September 18, 2026 that the European Union — European Medicines Agency's European Union — Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorization for Zeydovio…
Impact: The Danish drugmaker is the central actor, gaining a CHMP positive opinion for Zeydovio in short bowel syndrome that de-risks European approval and boosts its partnering and commercial prospects.
Sep 18, 2026 · 6 articles
4 5
Business
Zealand Pharma A/S, a biotechnology company, is conducting a share buy-back program initiated on May 7, 2026, and set to conclude by October 31, 2026. The program allows for repurchasing shares up to DKK 1.3…
Impact: Zealand Pharma is the issuer conducting the buy-back, repurchasing its own shares to return capital and reduce share count. The program signals balance-sheet confidence but is routine and already anticipated by the market.
May 26, 2026 · 75 articles
1 0
Business
Avacta Group Therapeutics, a clinical-stage biopharmaceutical company listed on AIM under ticker AVCT, announced on September 14, 2026 the appointment of seasoned biotechnology finance executive Mats Blom to its Board of Directors as a non-executive…
Impact: Former employer of Mats Blom, where he served as CFO from 2010 to 2019 and oversaw its Nasdaq listing and Copenhagen IPO; no direct impact from this event.
Sep 14, 2026 · 7 articles
2 0
Business
Apr 19, 2026 · 6 articles
4 0
Business
May 07, 2026 · 6 articles
4 0
Business
May 08, 2026 · 6 articles
Roche ↔ Zealand Pharma
Roche ↔ Zealand Pharma
ERGEN INTELLIGENCE
Track Zealand Pharma live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.